Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis
Identifieur interne : 001972 ( Main/Exploration ); précédent : 001971; suivant : 001973Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis
Auteurs : Mark J. C. Nuijten [Pays-Bas] ; Peter Van Iperen [Pays-Bas] ; Cynthia Palmer [États-Unis] ; Bob J. Van Hilten [Pays-Bas] ; Edward Snyder [États-Unis]Source :
- Value in Health [ 1098-3015 ] ; 2001.
Abstract
Objective The objective of this study was to examine the cost-effectiveness of a complementary treatment with entacapone versus usual care only in patients with Parkinson's disease.Methods The setting for this study was the Netherlands. A Markov process model was constructed to model the average quality-adjusted life years (QALYs) and the costs of both treatments. The model examined a period of 5 years in order to capture the influence of symptom improvement and disease progression. Data for the construction of the model were derived from published literature, including large, multicenter, randomized clinical trials in patients with end-of-dose motor fluctuations. Costs were obtained from published sources.Results The results of the baseline analysis showed that the use of entacapone as complementary therapy in Parkinson's disease slightly decreased the total average discounted costs from NLG 111,317 to NLG 110,038, while effectiveness increased from 2.42 to 2.56 QALYs (a 6 increase). In addition, entacapone substantially increased time without severe fluctuations by 0.63 years. Sensitivity analyses confirmed the robustness of these findings.Conclusion The study shows that entacapone is a cost-effective treatment in patients with Parkinson's disease: entacapone yields higher effectiveness in terms of both effectiveness measures (time without severe fluctuations and QALYs), while costs remain quite similar to those for usual care. The additional drug costs for entacapone are offset by reductions in other costs.
Url:
DOI: 10.1046/j.1524-4733.2001.44037.x
Affiliations:
- Pays-Bas, États-Unis
- Hollande-Méridionale, Hollande-Septentrionale, New Jersey, Washington (État)
- Amsterdam, Leyde
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis</title><author><name sortKey="Nuijten, Mark J C" sort="Nuijten, Mark J C" uniqKey="Nuijten M" first="Mark J. C." last="Nuijten">Mark J. C. Nuijten</name></author><author><name sortKey="Van Iperen, Peter" sort="Van Iperen, Peter" uniqKey="Van Iperen P" first="Peter" last="Van Iperen">Peter Van Iperen</name></author><author><name sortKey="Palmer, Cynthia" sort="Palmer, Cynthia" uniqKey="Palmer C" first="Cynthia" last="Palmer">Cynthia Palmer</name></author><author><name sortKey="Van Hilten, Bob J" sort="Van Hilten, Bob J" uniqKey="Van Hilten B" first="Bob J." last="Van Hilten">Bob J. Van Hilten</name></author><author><name sortKey="Snyder, Edward" sort="Snyder, Edward" uniqKey="Snyder E" first="Edward" last="Snyder">Edward Snyder</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F4551DAB111DD396AF2F87503F733300F45EFFB6</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1046/j.1524-4733.2001.44037.x</idno><idno type="url">https://api.istex.fr/document/F4551DAB111DD396AF2F87503F733300F45EFFB6/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000682</idno><idno type="wicri:Area/Main/Curation">000596</idno><idno type="wicri:Area/Main/Exploration">001972</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis</title><author><name sortKey="Nuijten, Mark J C" sort="Nuijten, Mark J C" uniqKey="Nuijten M" first="Mark J. C." last="Nuijten">Mark J. C. Nuijten</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>MEDTAP International, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Address correspondence to: Dr. Mark Nuijten, MEDTAP International, Dorpsstraat 75, 1526 LG Jisp, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: nuijtenmedtap@compuserve.com</wicri:noCountry></affiliation></author><author><name sortKey="Van Iperen, Peter" sort="Van Iperen, Peter" uniqKey="Van Iperen P" first="Peter" last="Van Iperen">Peter Van Iperen</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Novartis Pharma B.V., Arnhem</wicri:regionArea><wicri:noRegion>Arnhem</wicri:noRegion></affiliation></author><author><name sortKey="Palmer, Cynthia" sort="Palmer, Cynthia" uniqKey="Palmer C" first="Cynthia" last="Palmer">Cynthia Palmer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>MEDTAP International, Bethesda, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Van Hilten, Bob J" sort="Van Hilten, Bob J" uniqKey="Van Hilten B" first="Bob J." last="Van Hilten">Bob J. Van Hilten</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>LUMC, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Snyder, Edward" sort="Snyder, Edward" uniqKey="Snyder E" first="Edward" last="Snyder">Edward Snyder</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Value in Health</title><title level="j" type="abbrev">JVAL</title><idno type="ISSN">1098-3015</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="316">316</biblScope><biblScope unit="page" to="328">328</biblScope></imprint><idno type="ISSN">1098-3015</idno></series><idno type="istex">F4551DAB111DD396AF2F87503F733300F45EFFB6</idno><idno type="DOI">10.1046/j.1524-4733.2001.44037.x</idno><idno type="PII">S1098-3015(11)70041-9</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1098-3015</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective The objective of this study was to examine the cost-effectiveness of a complementary treatment with entacapone versus usual care only in patients with Parkinson's disease.Methods The setting for this study was the Netherlands. A Markov process model was constructed to model the average quality-adjusted life years (QALYs) and the costs of both treatments. The model examined a period of 5 years in order to capture the influence of symptom improvement and disease progression. Data for the construction of the model were derived from published literature, including large, multicenter, randomized clinical trials in patients with end-of-dose motor fluctuations. Costs were obtained from published sources.Results The results of the baseline analysis showed that the use of entacapone as complementary therapy in Parkinson's disease slightly decreased the total average discounted costs from NLG 111,317 to NLG 110,038, while effectiveness increased from 2.42 to 2.56 QALYs (a 6 increase). In addition, entacapone substantially increased time without severe fluctuations by 0.63 years. Sensitivity analyses confirmed the robustness of these findings.Conclusion The study shows that entacapone is a cost-effective treatment in patients with Parkinson's disease: entacapone yields higher effectiveness in terms of both effectiveness measures (time without severe fluctuations and QALYs), while costs remain quite similar to those for usual care. The additional drug costs for entacapone are offset by reductions in other costs.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Hollande-Méridionale</li><li>Hollande-Septentrionale</li><li>New Jersey</li><li>Washington (État)</li></region><settlement><li>Amsterdam</li><li>Leyde</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Nuijten, Mark J C" sort="Nuijten, Mark J C" uniqKey="Nuijten M" first="Mark J. C." last="Nuijten">Mark J. C. Nuijten</name></region><name sortKey="Nuijten, Mark J C" sort="Nuijten, Mark J C" uniqKey="Nuijten M" first="Mark J. C." last="Nuijten">Mark J. C. Nuijten</name><name sortKey="Van Hilten, Bob J" sort="Van Hilten, Bob J" uniqKey="Van Hilten B" first="Bob J." last="Van Hilten">Bob J. Van Hilten</name><name sortKey="Van Iperen, Peter" sort="Van Iperen, Peter" uniqKey="Van Iperen P" first="Peter" last="Van Iperen">Peter Van Iperen</name></country><country name="États-Unis"><region name="Washington (État)"><name sortKey="Palmer, Cynthia" sort="Palmer, Cynthia" uniqKey="Palmer C" first="Cynthia" last="Palmer">Cynthia Palmer</name></region><name sortKey="Snyder, Edward" sort="Snyder, Edward" uniqKey="Snyder E" first="Edward" last="Snyder">Edward Snyder</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001972 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001972 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F4551DAB111DD396AF2F87503F733300F45EFFB6
|texte= Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: A Markov Process Analysis
}}
| This area was generated with Dilib version V0.6.23. |  |